CEDARHURST, N.Y., Feb. 27, 2019 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues
the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in
these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff
and a preliminary estimate of their recoverable losses.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by
the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a
settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from
investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff
and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is
not required to partake in any recovery.
Bristow Group Inc. (NYSE: BRS)
Investors Affected: February 8, 2018 - February 12, 2019
A class action has commenced on behalf of certain shareholders in Bristow Group Inc. The filed complaint alleges that defendants
made materially false and/or misleading statements and/or failed to disclose that: (1) Bristow lacked adequate monitoring processes
related to non-financial covenants within its secured financing and lease agreements; (2) Bristow could not reasonably assure
compliance with certain non-financial covenants; (3) Bristow was reasonably likely to breach certain agreements; (4) Bristow had
understated its short-term debt; (5) the required corrections would materially impact financial statements; (6) there was a
material weakness in Bristow’s internal controls over financial reporting; and (7) as a result of the foregoing, defendants’
positive statements about Bristow’s business, operations, and prospects were materially misleading and/or lacked a reasonable
basis.
Shareholders may find more information at https://kclasslaw.com/securities/bristow-group-inc-loss-submission-form/?wire=3
Avon Products, Inc. (NYSE: AVP)
Investors Affected: August 2, 2016 - August 2, 2017
A class action has commenced on behalf of certain shareholders in Avon Products, Inc. In order to inflate its reported revenue
and representative growth metric during the Class Period, Avon engaged in an undisclosed scheme whereby it significantly loosened
its credit terms in order to recruit new representatives in Brazil, its largest market. Avon did not disclose the changes to its
credit terms in Brazil. Avon also failed to increase its allowance for doubtful accounts to account for the changes to its credit
terms in Brazil.
Shareholders may find more information at https://kclasslaw.com/securities/avon-products-inc-loss-submission-form/?wire=3
Conagra Brands, Inc. (NYSE: CAG)
Investors Affected: Pursuant to the SPO on or about October 9, 2018 and/or between June 27, 2018 and December 19,
2018
A class action has commenced on behalf of certain shareholders in Conagra Brands, Inc. The complaint alleges that defendants
failed to disclose material information, including that (i) Conagra inadequately performed proper due diligence in connection with
the acquisition of Pinnacle; (ii) the performance of Pinnacle’s three leading brands was not deteriorating due to intensified
competition, but to self-inflicted subpar innovation and executional missteps; (iii) Pinnacle’s business was performing so poorly
that it had resorted to pushing promotional deals to retailers in an effort to boost sales; and (iv) as a result of the foregoing,
Defendant’s public statements were materially false and/or misleading and/or lacked a reasonable basis when made.
Shareholders may find more information at https://kclasslaw.com/securities/conagra-brands-inc-loss-submission-form/?wire=3
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)
Investors Affected: November 4, 2015 - February 11, 2019
A class action has commenced on behalf of certain shareholders in Vanda Pharmaceuticals Inc. The filed complaint alleges that
defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Vanda was engaged in a fraudulent
scheme in which it promoted the off-label use of Fanapt and Hetlioz; (2) Vanda was fraudulently receiving drug reimbursements from
the government by abusing Medicare, Medicaid, and Tricare programs; (3) as a result of the scheme, Vanda faced legal action from
the government; (4) Vanda’s promotional materials for Fanapt and Hetlioz were false and misleading, garnering regulatory scrutiny
from the U.S. Food and Drug Administration; and (5) as a result, defendants’ statements about Vanda’s business, operations and
prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Shareholders may find more information at https://kclasslaw.com/securities/vanda-pharmaceuticals-inc-loss-submission-form/?wire=3
Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in
good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading
statements or the omission of material information by a Company lead to artificial inflation of the Company's stock.
CONTACT:
Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 334
Cedarhurst, NY 11516
Email: dk@kclasslaw.com
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967
